Evidence map›Paper›PMID 29369160›Full record

ArticleAIDS (London, England)2018

HLA-associated polymorphisms in the HIV-2 capsid highlight key differences between HIV-1 and HIV-2 immune adaptation.

Thushan I de Silva, Aleksandra Leligdowicz, Jonathan Carlson, Miguel Garcia-Knight, Clayton Onyango, Nicholas Miller, Louis-Marie Yindom, Stephane Hué, Assan Jaye, Tao Dong and 2 more

Open access · hybridAbstract read
In one paragraph

Article in AIDS (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Association ofFrontiers in genetics · 2022
    Article
  4. Molecular Biology and Diversification of Human Retroviruses.Frontiers in virology (Lausanne, Switzerland) · 2022
    Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 3 countries.

Thushan I de SilvaMedical Research Council Unit The Gambia, Banjul, The Gambia.
Aleksandra LeligdowiczMedical Research Council Unit The Gambia, Banjul, The Gambia.
Jonathan CarlsonMicrosoft Research, Redmond, Washington, USA.
Miguel Garcia-KnightNDM Research Building, Nuffield Department of Clinical Medicine, University of Oxford, Oxford.
Clayton OnyangoMedical Research Council Unit The Gambia, Banjul, The Gambia.
Nicholas MillerWeatherall Institute of Molecular Medicine, MRC Human Immunology Unit, John Radcliffe Hospital, Oxford, UK.
Louis-Marie YindomNDM Research Building, Nuffield Department of Clinical Medicine, University of Oxford, Oxford.
Stephane HuéLondon School of Hygiene and Tropical Medicine, London, UK.
Assan JayeMedical Research Council Unit The Gambia, Banjul, The Gambia.
Tao DongWeatherall Institute of Molecular Medicine, MRC Human Immunology Unit, John Radcliffe Hospital, Oxford, UK.
Matthew CottenMedical Research Council Unit The Gambia, Banjul, The Gambia.
Sarah L Rowland-JonesNDM Research Building, Nuffield Department of Clinical Medicine, University of Oxford, Oxford.
MRC Unit the Gambia · GMUniversity of Oxford · GBImperial College London · GBJohn Radcliffe Hospital · GBLondon School of Hygiene & Tropical Medicine · GBMedical Research Council · GBMicrosoft (United States) · USMRC Human Immunology Unit · GB

Funding

Medical Research Council G0600520Medical Research Council G0801751Medical Research Council G1001046Medical Research Council MC_U137884180Medical Research Council MC_U190085854Medical Research Council MC_UP_A900_1121Medical Research Council MC_UU_00008/11Medical Research Council MC_UU_12014/12Medical Research Council MR/L018942/1
6 · The paper itself

Abstract

objectiveHIV-1 frequently adapts in response to immune pressure from cytotoxic T-lymphocytes (CTL). Many HIV-2 infected individuals have robust capsid-specific CTL responses associated with viral control. Despite this CTL pressure, adaptive changes in this key immunogenic HIV-2 protein have not previously been described. We sought to compare selective pressure on HIV-1 and HIV-2 capsids and identify HLA-associated viral polymorphisms in HIV-2. DESIGN AND

methodsBioinformatic algorithms to identify sites under positive and negative selective pressure and a statistical model of evolution to identify HLA-associated polymorphisms in HIV-2 was applied to sequences from a community cohort in Guinea-Bissau. IFN-γ ELISpots were used to compare T-cell responses to wild-type and variant epitopes.

resultsWe identified greater purifying selection and less sites under positive selective pressure in HIV-2 compared with HIV-1. Five HIV-2 codons with HLA-associated polymorphisms were detected all within or around known or predicted CTL epitopes. One site was within the HLA-B58 SuperType (ST)-restricted epitope (TSTVEEQIQW), the HIV-2 equivalent of the HIV-1 TW10 epitope. In contrast to HIV-1, where a T→N mutation at position 3 is associated with resulting loss of CTL control, an E→D mutation at position 5 was observed in HIV-2. Robust CTL responses to the variant HIV-2 epitope were seen, suggesting that HIV-2 adaptation may be at the level of T-cell receptor recognition.

conclusionGreater constraints on evolution may exist in HIV-2, resulting in more purifying selection and different immune adaptation pathways in HIV-1 and HIV-2 capsids. This may allow CTL responses to persist in HIV-2.

Indexed as

Adaptation, BiologicalPolymorphism, GeneticCapsid ProteinsCase-Control StudiesEvolution, MolecularGuinea-BissauHIV-1HIV-2HIV InfectionsHumansImmune EvasionModels, StatisticalPhosphoproteinsSelection, GeneticT-Lymphocytes, CytotoxicCapsid ProteinsLa protein, humanPhosphoproteins

Identifiers

PMID29369160
PMCPMC5895130
OpenAlexW2792987508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.